Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab added to MBVP-based treatment for newly diagnosed primary central nervous system lymphoma
NL-OMON43562Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Jul 2010; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON43562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43562.